CompletedPhase 1

Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789

An Ascending Multiple Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NSA-789 Administered Orally to Healthy Subjects and Subjects With Alzheimer's Disease

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Asset

NSA-789

Listed sites

Recruiting sites

Enrollment

actual

Study population

Alzheimer’s disease

Key I/E criterion

•Healthy volunteers

Primary endpoint

•Adverse event monitoring as specific tests that will be done to monitor safety

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID3230A1-1002

NCT IDNCT00795730

Timeline

Milestones

Study first posted2008-11-21estimated

Study start2009-01actual (month precision)

Primary completion2009-05actual (month precision)

Study completion2009-05actual (month precision)

Last update posted2021-08-20actual

Assets

Drug assets

NSA-789

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age18 Years

Maximum age99 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Men or women aged 18 - 50 years (healthy subjects) or greater than 55 years old (subjects with Alzheimer's Disease)

•Women must be surgically sterile or postmenopausal

•Subjects with Alzheimer's Disease must be generally healthy, but may have a stable, chronic illness if well controlled

Exclusion criteria

•Healthy subjects may not be on any prescription or investigation drugs within 30 days of start of study.

•Subjects with Alzheimer's Disease may not be on any cholinesterase inhibitors such as donepezil (Aricept®) or rivastigmine (Exelon®) within 4 weeks of the start of the study.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

2 endpoints

Primary/protocol endpoint

Adverse event monitoring as specific tests that will be done to monitor safety (ECGs, certain laboratory tests, vital signs) and tolerability

Time frame:6 months

event count, event

Secondary/protocol endpoint

Pharmacokinetic and pharmcodynamic parameters

Time frame:6 months

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.